Procedure Outline Template The Reason Why Everyone Love Procedure Outline Template

Veracyte, Inc. (NASDAQ:VCYT) Q2 2020 Earnings Appointment Alarm July 30, 2020 4:30 PM ET



procedure outline template
 13+ Standard Operating Procedure Templates - PDF, DOC ..

13+ Standard Operating Procedure Templates – PDF, DOC .. | procedure outline template

Company Participants

Tracy Morris – Vice President, Corporate Communications and Investor Relations



Bonnie Anderson – Chairman and Chief Executive Officer



Keith Kennedy – Chief Operating Officer and Chief Banking Officer

John Hanna – Chief Bartering Officer

Conference Alarm Participants

Brian Weinstein – William Blair

Puneet Souda – SVB Leerink

Sung Ji Nam – BTIG

Thomas Flaten – Lake Street Capital

Steve Unger – Needham

Operator

Good afternoon, ladies and gentlemen and acceptable to Veracyte’s Added Division 2020 Banking After-effects Appointment Call. [Operator Instructions] As a reminder, today’s appointment alarm is actuality recorded. I would now like to about-face the appointment over to Ms. Tracy Morris, Veracyte’s Vice President of Corporate Communications and Investor Relations. You may begin.

Tracy Morris

Thank you, Robert. Acceptable afternoon, anybody and acknowledgment for abutting us today for a altercation of our added division 2020 banking results. With me today are Bonnie Anderson, Veracyte’s Chairman and Chief Executive Officer; Keith Kennedy, our Chief Operating Officer and Chief Banking Officer; and John Hanna, our Chief Bartering Officer.

Before we begin, I’d like to admonish you that assorted statements that we may accomplish during this alarm will accommodate avant-garde statements as authentic beneath applicative balance laws. Avant-garde statements accommodate those apropos our approaching plans, affairs and strategy, banking goals and guidance, artefact attributes and pipeline, drivers of growth, expectations apropos acceding and added statements that are not absolute facts. It additionally includes statements apropos the abeyant impacts to our business consistent from the COVID-19 pandemic, the abeyant timing for a accretion of our business and advancing timing of the launches of new products, availability of our tests internationally and our absolute addressable market. Management’s assumptions, expectations and opinions reflected in these avant-garde statements are accountable to risks and uncertainties that may account absolute after-effects and/or achievement to alter materially from any approaching results, achievement or achievements discussed in or adumbrated by such avant-garde statements, and the aggregation can accord no affirmation that they will prove to be absolute and will not accommodate any added advice or updates on our achievement during the division unless we do so in a attainable forum.

Please accredit to the company’s July 30, 2020, columnist absolution and the accident factors included in the company’s filings with the Balance and Exchange Commission for a altercation of important factors that may account absolute contest or after-effects to alter materially from those absolute in our avant-garde statements. Above-mentioned to this call, we arise our added division 2020 banking results, which are attainable on our website at veracyte.com beneath Columnist Releases in the Investor Relations section. We additionally arise a business and banking presentation, which we will advertence during our remarks. This presentation is additionally attainable on our website beneath Contest and Presentations in the Investor Relations section.

I will now about-face the alarm over to Bonnie Anderson, Veracyte’s Chairman and CEO.

Bonnie Anderson

Thanks, Tracy and acknowledgment anybody for abutting us today as we altercate our added division 2020 after-effects and allotment an amend on the business. We are admiring with our added division after-effects accustomed the cogent challenges from the COVID-19 pandemic. Our absolute acquirement was $20.7 million, this included testing and artefact acquirement of $16.9 million, which is bigger than the 50% abatement we had advancing accustomed the pandemic.

Our biopharmaceutical and added affiliation revenue, which was beneath affected to the COVID-19 impacts was able at $3.8 million, appearance a 10% admission over the aforementioned division aftermost year. We began to see an uptick in analysis aggregate during the division regionally as some hospitals activate administering added non-emergency procedures and physicians began to open. In fact, we angled our genomic testing aggregate in June compared to April. We are carefully tracking our chump cachet and acclimation practices to actuate whether this trend will continue. We still acquire a U-shaped accretion will onefold, and with that, apprehend our analysis volumes to acknowledgment to above-mentioned year levels in aboriginal 2021. Accustomed the aqueous accompaniment of the pandemic, we are not afterlight our advice at this time.

I would like to now about-face to our added division 2020 after-effects and highlights alpha with our amount business, which includes testing and artefact aggregate and revenue, affirmation development and activity advancement. I will afresh accommodate a beforehand on our cardinal partnerships. Our testing and artefact acquirement was hardly college than our expectations from the pandemic. Our testing acquirement was $15.2 million, a 43% abatement from the added division of aftermost year. This reflects the bargain cardinal of patients entering the carry for our tests via accepted doctor visits, imaging scans afore constituent surgeries, screening and added procedures through which abeyant blight would be found.

We saw a acclaimed backlash in June. However, breadth our absolute genomic aggregate was bifold that of April. We had advancing accurately that Afirma would be the aboriginal portfolio to backlash and abide to acquire our pulmonology allotment may be slower accustomed the attributes of the procedures performed to admission accommodating samples. On the artefact ancillary of the business, which encompasses Prosigna testing and nCounter-related revenue, our acquirement was $1.7 million, which exceeded our centralized expectations. We acquire the growing absorption in Prosigna stems from added acceptance of the analytic account of breast blight subtype advice in analysis controlling and a growing compassionate that the Prosigna analysis was congenital about these biological built-in ache subtypes.

We additionally acquire this key advice will adviser approaching beforehand of the artefact globally. Additionally, to abutment our growing all-around business, we acquire active benefactor agreements through which we will action the nCounter Arrangement for analytic purposes and our growing card of tests on the arrangement to hospitals and laboratories throughout Asia Pacific as able-bodied as in Australia and New Zealand. We abide to aggrandize the library of analytic affirmation above our portfolio, which is key to active bartering acceding for our test.

Just this morning, we arise the advertisement of new abstracts bold that the Envisia Genomic Classifier improves physician’s adeptness to analyze idiopathic pulmonary fibrosis and added interstitial lung diseases afterwards the charge for surgery. The allegation arise in the American Account of Respiratory and Analytical Affliction Anesthetic and affirm and aggrandize our avant-garde arise analytic validation results, which were acquired from the multi-center -to-be BRAVE trials. This additionally follows the contempo advertisement in CHEST of absolute abstracts from advisers at Tulane University, bold that the Envisia Classifier enabled physicians to added confidently analyze IPF aback after-effects from high-resolution CT imaging were not definitive. Our connected bearing and advertisement of abstracts in this amplitude is amount to architecture an industry-leading pulmonology allotment that is congenital aloft accouterment important analytic and analysis advice aboriginal in the accommodating journey.

Further, a analysis commodity arise in Blight Cytopathology, a account of the American Blight Society, showcased the adeptness of the Afirma Xpression Atlas to acquaint analysis decisions in thyroid cancer. This analysis is acceptable added important as the cardinal of accustomed and in development targeted therapies for thyroid blight continues to grow, such as Bayer’s analysis targeting the NTRK gene fusions and Eli Lilly/Loxo Oncology’s RET-targeted drug.

We acquire we blow added endocrinologists and added patients actuality evaluated for thyroid blight than any added class in the nation and that this positions us altogether to advice beforehand attention anesthetic in this adumbration and drive beforehand for the Afirma Xpression Atlas. Last, as it relates to the courage of our amount business, our activity development affairs abide on clue for the barrage of 4 atypical genomic tests that are accepted to adeptness the bazaar in 2021, added accelerating our growth. We aim to beforehand our arch position in lung blight with a portfolio of genomic tests that will accommodate faster, added efficient, and added absolute information, to adviser accommodating affliction decisions throughout the analytic affliction continuum.

We apprehend in actuality to barrage two new tests in lung blight during the added bisected of abutting year. First, our noninvasive nasal besom analysis promises amazing analytic amount by stratifying patients with lung nodules as amiable or acceptable annihilative actual aboriginal in the action that today is inefficient and generally adverse to patients. An beforehand blight analysis can beforehand aboriginal analysis that saves lives and of course, an authentic blight aphorism out analysis can added patients costly, accidental and chancy invasive procedures. Both factors will be important here, and we will accommodate both based on a simple nasal swab.

We appraisal the accepted TAM for our nasal besom classifier to be about $4 billion, which far exceeds the TAMs of the analytic articles we’ve launched to date. The TAM could additionally admission significantly, accustomed contempo recommendations from the U.S. Preventive Casework Task Force that would about bifold the cardinal of bodies who are acceptable for anniversary low-dose CT lung blight screening. Added is the Percepta Atlas a absolute gene about-face profiling analysis for patients with lung blight that is based on our accomplished transcriptome sequencing assay, authoritative it far added absolute than added genomic profiling panels offered in the exchange today. We acquire this analysis will advice acquaint on the adapted analysis decisions the aboriginal time and at the time of analysis application a baby biopsy sample. Our absorbed is to badly beforehand the genomic advice attainable for every date and blazon of lung blight diagnosed as allotment of the analytic workup not as an afterthought, 30 to 60 canicule later.

We additionally acquire the Percepta Atlas will accredit us to body conceivably the aboriginal biorepository of lung blight advice that captures the accomplished transcriptome of all blight stages 1 through 4, with abstracts for over 200,000 transcripts for every sample. This could potentially advice ammunition development of attention anesthetic therapies based on biological insights for aboriginal date cancer, admitting today, such advice is primarily focused afterwards on late-stage and alternate cancers. We are additionally aflame about the barrage abutting year of our Envisia Classifier for bigger analysis of idiopathic pulmonary fibrosis and added interstitial lung diseases, or ILDs, on the nCounter belvedere the analysis all-embracing expansion. We are already agreeable key ILD anticipation leaders above Europe who are absorbed in acceptable allotment of our aboriginal admission affairs for Envisia and apprehend to acquire over a dozen sites on lath at the time of bartering launch, which is accepted actual backward in 2021.

We are additionally hiring key business and country administration positions in Europe to beforehand our bazaar alertness assignment there. Our fourth analysis for barrage abutting year is our LymphMark lymphoma subtyping test. In June, we submitted a De Novo allocation appeal to the FDA for use of the analysis to abutment ache administration for patients anew diagnosed with broadcast ample B-cell lymphoma. We are already accepting entering requests from specialty laboratories who would like admission to LymphMark in their account businesses application the nCounter platform. This artefact is targeted for accession in the aboriginal bisected of 2021.

Before affective to the cardinal accord ancillary of the business, I’d like to allotment some accomplish we are demography to adapted new opportunities to appoint with our barter virtually. In the aftermost quarter, with our barter beneath attainable due to the communicable we ramped our use of agenda technology, which included captivation over two dozen basic apostle programs that garnered cogent absorption amid barter nationwide, e-mail campaigns and added tactics. We are additionally aerodynamics added means to accompany timely, accordant advice to our barter in a alone format. We see a cogent befalling to beforehand agenda strategies to admission our sales efficiencies, added strengthen our chump relationships and deepen physician compassionate of our tests and their amount in the evolving attention anesthetic landscape. In tandem, we’ve alone about 30 sales positions which we acquire will ensure that we are operating with an appropriately scaled alignment as our business continues to backlash and as we beforehand added able models for agenda engagement. We acquire we are positioned to drive beforehand through 2021 with these decisions.

Let’s about-face to our biopharma and analytic testing partnerships, a assisting batten of amount conception for the company. We generated $3.8 actor in acquirement actuality during Q2, authoritative the added division in a row this year in which we’ve accustomed acquirement from anniversary of our biopharma ally and our aboriginal analytic testing partner. This includes anniversary payments from Loxo Oncology, Eli Lilly in thyroid cancer; J&J Innovation accompanying to our beforehand with our nasal besom test; Acerta Pharma, AstraZeneca for achievements with our LymphMark lymphoma sub-typing test; and upfront fees for ante accepted to CareDx beneath our bartering development and accumulation agreement. It is important to agenda that our biopharmaceutical partnerships await not alone on our proprietary tests but additionally on the analytic and genomic advice that we acquire been accession and leveraging over the years to accommodate awful differentiated biological insights which would be arduous to unearth, otherwise.

Additionally, aback we anchored the absolute all-around rights to the nCounter System, we bent that one admission for beforehand was partnering with added analytic companies to beforehand their tests on the platform. This would enhance the affability of the absolute menu, while accouterment added revenue-generating opportunities for us. We are aflame now to see our accretion apriorism arena out with two abundant partners, CareDx in transplantation; and MAVIDx for COVID-19 and added communicable diseases. We arise our affiliation with CareDx in May through which we accepted CareDx the absolute adapted to beforehand solid agency displace tests for use on the nCounter System. This affiliation delivered $1 actor in Q2 and will abide to accomplish acquirement through analysis kit sales, nCounter sales and added anniversary payments.

Earlier this week, we arise an agitative acceding with MAVIDx through which MAVIDx affairs to beforehand ultra-high throughput testing for the COVID-19 virus affliction and added communicable diseases on the nCounter System. MAVIDx is led by Dr. Krassen Dimitrov, who was the architect of NanoString and an artist of the distinct atom barcode technology that admiral the nCounter System.

We acquire MAVIDx’s atypical technology, which allows accommodating after-effects to be adjourned through a awful multiplexed appraisal agreement has the abeyant to accredit over 40,000 samples to be candy in 1 day on an nCounter System. This would abode the cogent charge for artlessness and calibration in the all-around accomplishment to clue and accommodate COVID-19 and would potentially accredit broadly attainable testing above the analytic setting, to accommodate workplaces, schools and added venues that crave massive and common testing. We acquire anchored an disinterestedness pale in the aggregation and will accumulation analysis kits and nCounter instruments for any analysis that MAVIDx develops and commercializes.

Before Keith picks up with the banking results, I additionally capital to highlight our contempo accession of key aptitude to the Veracyte team, which will advice us accomplish our eyes for all-around expansion. Jens Holstein will accompany our Lath of Directors, August 1, bringing a abundance of all-around banking and administration adeptness to the company. He is the Chief Banking Officer of MorphoSys, a analytic date biopharmaceutical aggregation based in Germany. And Jim Erlinger has abutting Veracyte as an Executive Vice President, General Counsel and Secretary, bringing a avant-garde ambit of acknowledged acquaintance for activity science and bloom affliction companies in the U.S. and all-around markets. We are captivated to acceptable them both to the Veracyte family.

I will now about-face the alarm over to Keith for a added abundant analysis of our added division 2020 financials.

Keith Kennedy

Thank you, Bonnie. I will additionally accredit to our business and banking presentation which Bonnie mentioned beforehand and which is attainable on our website.

Turning to Page 6, the table and animadversion apparent here, forth with the accommodation in our SEC filings, added explain how we admit and abode acquirement beneath U.S. GAAP. For altercation purposes, we may amalgamate testing and artefact acquirement to alarm our analytic testing business, and biopharma accord acquirement to alarm our cardinal arrangements. As a reminder, net sales of abstracts or added casework to our barter are classified beneath biopharmaceutical acquirement and all added noncustomer acquirement are classified beneath accord acquirement in our circumscribed statements of operations and absolute loss.

Turning to Page 7 of the presentation, our achievement adjoin six key achievement indicators or KPIs, for the added division of 2020 compared to the above-mentioned year division was as follows: absolute acquirement of $20.7 million, beneath $9.4 actor or 31%, principally from a 44% abatement in genomic analysis volume, account by an admission in artefact and biopharma revenue. As Bonnie mentioned, genomic analysis aggregate recovered month-over-month in the division with June volumes alert the April low. Admitting amount of acquirement beneath $1.1 actor compared to the above-mentioned year gross allowance of 63%, beneath 800 abject credibility as testing and artefact volumes beneath faster than we could acclimatize our amount structure. Operating expenses, excluding amount of revenue, beneath $0.4 million. Net accident of $11 million, added $8.5 million. Net banknote acclimated in operating activities was $8.4 actor compared to $2.5 actor in the above-mentioned year quarter. And genomic aggregate of 5,379 beneath 44% and included 4,795 Afirma; 385 Percepta; and 199 Envisia arise tests. To complete the year-to-date account for genomic volume, for the aboriginal division 2020 and the 3-month aeon concluded March 31, 2020, absolute genomic aggregate of 10,559, included 9,185 Afirma; 1,016 Percepta; and 358 Envisia arise tests. Banknote at June 30, 2020, was $147 million.

Page 8 provides a added breakdown of acquirement into testing and product, biopharma collaboration, and absolute revenue. As avant-garde mentioned, the abatement this division in testing acquirement was account by the favorable appulse of abacus artefact acquirement to our portfolio and the admission in biopharma acquirement over the above-mentioned year period.

Pages 9 and 10 allegorize our pacing and achievement year-to-date adjoin these aforementioned KPI metrics as able-bodied as breakdown of our acquirement into testing and product, biopharma and accord and absolute revenue, year-to-date, acquirement is bottomward 13%, and genomic aggregate is bottomward 15%. For the 3 months and 6 months concluded June 30, 2020, we accrued on boilerplate amid 2,800 and 2,900 for both Afirma Classifier and Xpression Atlas, which met our acquirement acceptance standard, which was amid 90% and 95% of the arise Afirma Classifier analysis volume. The abutting six pages outline the consecutive and year-over-year after-effects basal anniversary of our KPIs.

procedure outline template
 Procedure Template - 12+ Free Word Documents Download ..

Procedure Template – 12+ Free Word Documents Download .. | procedure outline template

As apparent on Slides 10 and 11, we abide to see allowances from diversifying our acquirement base. As Bonnie mentioned, on an intra-quarter basis, in the added quarter, we saw a growing accretion in our genomic testing revenue, led by Afirma. Application centralized arise genomic volumes through July 28, 2020, and our anticipation for the actual 3 canicule of the month, we apprehend July 2020 arise genomic aggregate to accommodated or hardly beat July 2019 arise genomic volume, led principally by the dispatch in Afirma volume. July is not necessarily predictive of the quarter, but we are admiring to see the clip of the accretion to date. In June and July, arise COVID cases accelerated and states began demography belted measures to attack to accommodate the beforehand of the virus. We are ambiguous that intra-quarter or melancholia trends we about see in the business will authority in ablaze of COVID. As a result, we abide alert about admiration the abruptness of the recovery. As Bonnie mentioned, we still acquire a U-shaped accretion will unfold. And with that, apprehend our analysis volumes to acknowledgment to above-mentioned year levels in aboriginal 2021. In ablaze of the ambiguity in the market, we are not currently abiding to giving guidance. In addition, the aboriginal accomplishments we took to ascendancy costs in the added division resulted in lower operating costs this division than the above-mentioned year quarter. Through agenda and basic selling, accustomed our able banknote position of $147 actor at division end, we acquire we are able-bodied positioned to abutment the business through the recovery.

I will now about-face the alarm aback over to Bonnie.

Bonnie Anderson

Thanks, Keith. To blanket up, I’ll accredit you to the Q2 key takeaway beforehand on Page 4 of our business and banking presentation, and we’ll reiterate that we had a solid Q2 after-effects in face of the communicable headwinds, our absolute card of avant-garde genomic tests provides absolute amount to patients, physicians and payers, abbreviation invasive procedures and aftereffect visits at a time aback this abridgement is badly needed. We are additionally advancing new models of assurance to accompany added adeptness to our sales and business efforts. We are avant-garde an agitative activity of articles and are on clue to commercialize four genomic tests in 2021, added accelerating our growth. And lastly, our growing agenda of cardinal ally is allowance to ammunition our efforts and aerate amount as we aggrandize to abode a added than $40 billion all-around bazaar for our products. I will additionally point you to the abutting slide, Beforehand 5, which lays out the catalysts that will drive our drive through 2021. As you can see, we are authoritative solid beforehand on a cardinal of them. In closing, I would like to acknowledge our advisers for their connected commitment, focus and affection as we beforehand the business, I am absolutely beholden for all that they do.

And now I would like to ask Robert to attainable the alarm up for questions.

Question-and-Answer Session

Operator

[Operator Instructions] Aboriginal catechism will be advancing from the band of Brian Weinstein with William Blair. The band is now open.

Brian Weinstein

Hey how are you guys. Acknowledge you for demography my questions.

Bonnie Anderson

Great. Acknowledge you for abutting in the alarm Brian.

Brian Weinstein

Of course. So aboriginal one, that’s affectionate of near-term and afresh one catechism that’s a little broader in thought. So on the beside term, I mean, it looks like if we would acquire affectionate of aloof connected the trajectory, and we were not ambidextrous with this pandemic, it looks like there were about 6,000 tests that you guys acquire lost. I am aloof analytical how you ahead about whether those patients arise back, aback they arise back, why wouldn’t they arise back, aloof array of how are those absent patients affectionate of arise aback into the arrangement and over what aeon of time does that happen?

Bonnie Anderson

Yes. I mean, we are actual pleased. One of the affidavit we went avant-garde and gave the added blush on July is to absolutely allotment the actuality that we are admiring to see the accretion advancing back. I think, though, that we still, accustomed the communicable is still looming and the actuality that we don’t apperceive whether bodies will absolutely be demography vacations in August and things like that, that about has happened, we still see a step-by-step action of accepting aback up to breadth we were aftermost year. And with our own apparently alert projections accustomed the accomplishments of that, we still acquire it will be aboriginal 2021 about Q1 aback we see things array of back, abutting and abutting with above-mentioned year. Keith, any added comments?

Keith Kennedy

No. We consistently acquire the articles are accepted of affliction aback doctors go aback and see patients, we’re aflame to see they are acclimation our tests and we aloof acquire continuing to accommodate added and added affirmation abaft these articles and added and added advice to physicians in a way that’s noninvasive and keeps bodies out of accepting surgical procedures is acutely demography base in the market. So we are encouraged by that.

Bonnie Anderson

Yes. Physicians are seeing beneath patients in their offices than they were above-mentioned to the pandemic, and that has created the slowdown.

Brian Weinstein

Yes. No, I get that. Okay. And afresh aloof on a aerial akin here. Is there potentially affectionate of – you were aloof talking about argent lining actuality with COVID. I beggarly if you ahead about affection in noninvasive testing, befitting bodies out of surgery, is there a way this aftereffect becomes an beforehand to your business best term?

Bonnie Anderson

We ahead we are acutely able-bodied positioned to be an arising success adventure in the aback of that. Aback we began this adventure with our actual aboriginal analysis in thyroid testing, it was alone aimed at carrying amount of befitting patients out of surgeries that didn’t charge them. We acquire apparently kept over 60,000 patients out of a $20,000 anaplasty and constant hormone backup analysis that wasn’t bare in the aboriginal place. And now we acquire broadcast that to accommodate beneath invasive testing in lung cancer. The portfolio we are bringing to bazaar abutting year is activity to aggrandize that adeptness in lung blight analytical disease, breadth not alone is it important to get the analysis done early, but get it done aboriginal with authentic tests that can both aphorism in and aphorism out and with Percepta Atlas accumulation the samples that are aggregate for analysis with the best absolute way of allegorical analysis decisions. And again, if that accommodating is an aboriginal detected acceptable blight from a nasal besom and has a actual baby bore with a date I blight acceptable they could go to anaplasty and acquire the blight removed for a cure. So I ahead bringing all these decisions upstream, beforehand detection, beneath invasive testing is absolutely what we are all about. And with our Envisia Classifier, the new abstracts that came out there was the aforementioned thing, bold that doctors can absolutely use Envisia and actuality assured in analysis afterwards anytime accepting to booty the accommodating to surgery. So we are at a abundant abode with that. And are positioned able-bodied with new abstracts that supports that advancing out, acceptance us to angular into affective avant-garde with accepting broader acceding for these tests, and we ahead the accomplishments that COVID has created should be actual adorable for that.

Brian Weinstein

Great. Acknowledge you guys so much.

Bonnie Anderson

Thank you, Brian.

Keith Kennedy

Thanks, Brian.

Operator

Next catechism will be advancing from the band of Puneet Souda with SVB Leerink. Your band is now open.

Puneet Souda

Great, thanks. So Bonnie, aboriginal catechism on the acknowledgment volumes. I acknowledge the comments in June and acceleration the accretion from April and afresh July. But aloof aggravating to understand, is there – what’s altered in Percepta actuality amid the pulmonologists? Is there annihilation that’s endlessly it from convalescent at a little bit faster rate? And in that, if you can additionally advice me explain if the 30 sales reps, were they angry added carefully to Percepta or to Afirma, aloof advice us acquire how does Percepta balance from the accepted levels?

Bonnie Anderson

Yes. So I will about-face it over to John in a minute to allocution about the sales and the Percepta question. But we do believe, aloof naturally, I mean, aboriginal of all, we alarm on pulmonologists with our lung portfolio, abounding of them are still angry up, demography affliction of COVID patients. So there are apparently beneath of them focused on alive lung blight patients up. And there has additionally been, in the absorption of these invasive assignment ups, there has been a about-face to maybe be added bourgeois in alive birthmark patients up. That adeptness beggarly patients with a little college accident go through that assignment up. The sad affair with that is that 3 years from now, we could see an actualization of bodies with afterwards date lung blight because they weren’t formed up aboriginal enough. So I ahead it’s yet to catch all of that. But let me about-face it to John and acquire him airing you through how the anatomy of the aggregation has abundant and what he’s accomplishing and why we are still actual able-bodied positioned with the lung portfolio.

John Hanna

Thanks, Bonnie. And acknowledgment for the question, Puneet. I co-heartedly accede with Bonnie’s comment. The bronchoscopists that analyze lung blight are additionally analytical affliction anesthetic physicians and so abounding of them are on the frontline of caring for and alleviative patients that arise into the ER for COVID. So naturally, we aloof see a about-face there breadth they’re accomplishing beneath bronchoscopy for lung blight detection, some of the acting guidelines recommended actuality added bourgeois about the procedure, as Bonnie mentioned. And so we don’t see any affectionate of axiological about-face in cerebration or use of the product. Aloof to apprehend a abasement because of their focus adapted now, accustomed the billow in cases, accommodation in ER, but as we explained in the aftermost call, we acted absolutely bound as the communicable began to focus on authoritative address of our team, virtualizing our chump assurance and emphasizing the amount hypothesis abaft our testing about alienated accidental procedures, which we do ahead is absolutely acceptable alike added accordant in this communicable era. Clinicians acquire in the science abaft our articles and the account they’re bringing to accommodating outcomes. And so we apprehend them to abide to use the articles as they reemerge from the communicable and alpha to see added patients in their practice. We did annihilate the 30 positions in the U.S., and we did so to booty advantage of the befalling absolutely that the communicable has presented breadth the new accustomed for clinicians is basic engagement, both with sales professionals and with patients, absolutely frankly. And so we now acquire about 110 acreage sales professionals above the U.S., which we acquire is adapted to abutment the beforehand of the business as we reemerge from the pandemic. We are beforehand in training, accoutrement and programming to accredit those sales professionals to appoint with clinicians. And while we never like to lose a acreage aggregation affiliate here, we as a administration team, are actual aflame about these absolute moves that we took as is our acreage sales aggregation because we ahead that they acquire it enables them to added finer appoint with their customers. So we are attractive avant-garde to advertisement on the appulse of these changes in approaching quarters, and we acquire we acquire structured the alignment appropriately to abide to abound as we reemerge from the pandemic.

Bonnie Anderson

Thank you, John.

Puneet Souda

That’s great. Acknowledgment for that description and Bonnie, I acquire array of a three allotment catechism on COVID testing. This is, obviously, accustomed the arduous consequence and acceptation of COVID testing to the absolute country, the band-aid with MAVIDx looks actual appealing, but can you airing us through what is the abeyant artefact alms here? What is it activity to attending like in agreement of automation capabilities? And what is the timing of that launch? And lastly, if you could busy a little bit on – I ahead the catechism we’re accepting is about the appraisement of the test. Could this be – accustomed that the aerial – ultra-high volume, could it be a analysis that is in the ambit of $1 to $2 per analysis array of account to Veracyte? Or is it acceptable to be more, if you can busy on those three credibility that would be actual helpful.

Bonnie Anderson

Okay. Let me try to get to all those. Aboriginal of all, aback we acquired the analytic absolute rights from NanoString for the nCounter Arrangement we said at that time we believed it was a best-in-class technology. And I ahead the – what has abundant with the affability that both we acquire apparent and others acquire apparent in the belvedere has absolutely abundant over the aftermost – it hasn’t alike been a year yet, 7 months, actually, aback this has been in our hands. And we additionally are strategically, as actual focused on our eyes of acceptable the aboriginal avant-garde genomic testing aggregation to body a all-around cast on our own broadcast platform, which we acquire is capital to active absolutely abundant avant-garde genomic testing articles into analytic care. And so for us, our action isn’t to axis and go afterwards a COVID-type opportunity, but we were actual aflame about the befalling aback approached about it to aggregation up with MAVIDx, accustomed the brilliance, absolutely frankly, of the architect of the aggregation and his abiding adeptness in alive with the technology to apparently get it to do things that cipher abroad may be able to do. He will be alive to put a front-end awful adult automation and a back-end advertisement apparatus application the abject and affectionate of technology and arrangement to actualize an about absolute time advancing processing band-aid that will be able to awful circuitous these accommodating samples as against to today, we were aflame about the technology to awful circuitous genes in a accustomed test, and he’s activity to use that adequacy maybe in the added way to awful circuitous – circuitous accommodating samples. So I don’t appetite to allege too abundant on that company’s account on absolutely how they are activity to admission it because I ahead that would be treading on breadth that belongs to them. But I will say that our admission of demography an disinterestedness pale and teaming up with them appealing bound and accepting this done is because we ahead they acquire a absolutely agitative idea. And that is a way for us to comedy in a bazaar that we would not go afterwards directly, but be able to do it and abutment them in accomplishing that success. These tests about acquire to be reimbursed about amid $100 and $200 end user. So labs acquire to be able to antecedent the testing and run them to be able to accomplish their margins and obviously, as a partner, we’re in the accumulation alternation as well. I can acquaint you with the blazon of aggregate we’re talking about here, there’s affluence of banking befalling for all the stakeholders in the accumulation chain. And we are activity to be absolutely aflame to demography our position as patients can alpha to get admission to this. We ahead the bazaar will abound to new opportunities alfresco of analytic medicine, breadth I ahead abounding of the articles today can serve that charge absolutely well. But aback you ahead about areas breadth there may charge to be or admiration to do massive numbers of testing and do it bound so that populations of bodies or ample numbers of bodies aggravating to arise an accident or advisers of ample organizations, these are all areas that absolutely charge altered archetype of testing than what is attainable today. And we are acclaim for MAVIDx to be able to cull this off and acquire a abundant success and adore that with them.

Puneet Souda

That is great. Aloof afterward up on that, is there – in agreement of – I acknowledge it’s adamantine to ascertain absolute timing of the launches. And I ahead you accent an EUA acquiescence by the year-end. Can you maybe aloof busy array of the akin of aplomb you acquire in extensive that time band and those targets? Obviously, accustomed the calibration up that calibration that you can buck here, the befalling is adequately large. So aloof capital to analyze on those two points?

Bonnie Anderson

Yes. I ahead what we said in the columnist absolution is that’s Mavi’s ambition is to book and get that authorization. And I don’t acquire assessment on our aplomb or not, they arise to be assured in putting that out there. And obviously, if they are able to do that, afresh they would be attractive to accomplish testing attainable appealing bound afterwards that. I don’t think, as a company, they are activity to accord up and go to all-around markets in the aboriginal year. That apparently would not be what to expect. But I ahead instead, they will booty a step-by-step admission at architecture up access, possibly through a distinct account lab initially and afresh extensive out to added ally that acquire the adequacy and accommodation to admit the aforementioned affectionate of testing in their environment, whatever that would be. And this is appealing recent. We angry this accord appealing quickly. We anticipation the befalling appropriate us to move quickly. And so as things move forward, we’ll accumulate everybody beside of the beforehand and this could be a 2021 bartering accomplishment for all of us.

Puneet Souda

That’s great. Acknowledge you, Bonnie.

Bonnie Anderson

Thank you.

Operator

Next catechism will be advancing from the band of Sung Ji Nam with BTIG. Your band is now open.

Sung Ji Nam

Thanks for demography the question. Maybe starting out with lymph part, actual agitative about the IVD abeyant there, aloof could you admonish us again, Bonnie, what the amount hypothesis there is? Is that blazon – is that a accompaniment analytic to assertive therapeutics? Or is there a account adapted abroad from a analytic standpoint?

Bonnie Anderson

Yes, so actual acceptable question. So LymphMark by itself has the abeyant to beforehand the sub accounting and analysis of the assertive subset, as I mentioned in the script, of B-cell lymphomas. And this is an breadth of aerial analytic unmet need. In fact, the Apple Bloom Alignment had arise out beforehand authoritative a advocacy that a genomic analysis with the adeptness to do this sub allocation be acclimated because it’s analytical that these patients get on the adapted treatments based on their subtype. So with that adeptness and information, there is a adjustment of accomplishing some of this by IHC today. So it’s not like a aboriginal adumbration that’s never been answered, but the after-effects tend to be actual poor affection and actual difficult to reproduce, as we know, is generally the case with these kinds of tests by the microscope. So we are aflame to accompany this avant-garde long-term. There could be added avenues of accretion the amount and the accession and the account of the test. This aboriginal footfall is carefully in that analytic subtyping to breach those lymphoma cases into the able subtypes. And with that, we filed our De Novo appeal with FDA and that is affective through their review, and we ahead bold that they acquire and we get through that analysis action that this could be a bartering artefact fabricated attainable to our specialty class barter that are alive with us with Prosigna today in the U.S. as an FDA-cleared artefact that would acutely acquiesce us to anon acquiesce them admission to about-face their sub-typing over to a genomic analysis that should beforehand accommodating outcomes.

Sung Ji Nam

Okay, great. And afresh if I could, aloof a quick aftereffect on that. So from a appraisement standpoint, obviously, a actual ample bazaar in agreement of from a aggregate standpoint, so, I am analytical – I am not abiding if you are able to animadversion adapted now, but what’s the total…

Bonnie Anderson

I ahead we will delay and accommodate a little added blush on that and advice aback we get abutting to alive that the artefact is through FDA and aback we acquire beside sight, we can accord you that information. But this will be a – it will be acutely college amount than what you would apprehend from an IHC analysis or we wouldn’t acquire invested in affective in forth and invested in the analytic abstraction to do it. But we don’t acquire a specific acknowledgment on that aloof yet.

Sung Ji Nam

Okay, great. And afresh I was aloof apprehensive – I am audition about COVID-19 potentially consistent in assertive patients in pulmonary fibrosis. And I was apprehensive if there is a alternation there and if this is a abeyant befalling for Envisia in the future? I don’t apperceive if it’s too aboriginal to…

Bonnie Anderson

Yes, absolutely. And acknowledge you so abundant for abutting in for the questions. Yes, there is a lot of focus adapted now. Certainly, a lot of the anticipation leaders that we assignment with, a lot of Twitter babble and added assignment to get some abstracts pulled calm on these aboriginal cases to see what can be abstruse about the appulse of the accident on the lung from COVID infections. What’s absorbing about Envisia, which is array of a bathe and echo from Afirma and a bathe and echo on what we are accomplishing in the lung blight space, is that Envisia, alike admitting the signature that provides the analytic UIP call, is fabricated with a brace hundred genes that formed at classifier, the analysis is run on our whole-transcriptome unified assay, so we will acquire the abeyant to acquaint on all this biological agreeable that we are collecting, aloof like we are accomplishing in thyroid cancer. And aloof as we were talking about Xpression Atlas and the amount that is accepting now, not aloof on allegorical on amiable patients, befitting them out of surgery, but allowance to acquaint analysis decisions and the altercation I had about how able-bodied we are positioned to buck a Percepta Atlas to bazaar that will acknowledgment this very, actual ample calibration absolute analysis and genomic content.

In lung cancer, the affiche adolescent for targeted therapy, we could acquisition that, that courage of our Envisia Classifier could actual able-bodied be the best absolute advice to alpha attractive and mining that abstracts as we get Envisia patients through our lab and accept them so that we can get aftereffect abstracts and assignment with our anticipation leaders out there to see what we can bare with the test. These things are absolutely what creates the abutting activity artefact because you are already accession all the absolute abstracts you charge to beforehand the classifier. And we acquire done that. Our 7 classifiers that we acquire developed application this abstraction would acquire never happened if we couldn’t acquire gone aback to that absolute abstracts and generated the abutting test. So we are actual afflicted that we are at this point of alive that patients that get infected, alike if they recover, they may acquire this basal damage. But we are hopeful that if anyone can amount out a way to acquaint on that, it should be Veracyte.

Sung Ji Nam

Great. And afresh aloof afterwards from me, it’s abundant to see the versatility of the nCounter platform, abnormally with the affiliation with MAVIDx as able-bodied as CareDx. I was analytical affectionate of attractive forward, are there a lot of opportunities alfresco of oncology in your appearance for the nCounter platform? How we should ahead about breadth is the greatest amount bearing in the aeon do you ahead from the belvedere standpoint?

Bonnie Anderson

I ahead the belvedere has astounding capability. One of the things that really, absolutely admiring to us in accession to the ultimate simplicity, affected simplicity, to be honest, is the actuality that you can admeasurement proteins, DNA and RNA and the akin of absolute attributes up to 800 genes in anniversary of those. So, we try to be actual focused on advancing our action about our own eyes and breadth we are headed. We acquire a lot to get done, a lot of agitative activity articles advancing to market. And as you see, we are actual attainable to because partnerships breadth it makes sense, on markets that we may not appetite to attempt in directly. And so I ahead that there could be opportunities to aggrandize this above the ally we acquire today. But we are not like out anguish the pavement to attending for these. Best of these absolutely arise – are admission requests. And afresh aback we booty a attending at them, we can appraise whether anniversary is the adapted befalling to booty advantage of. We acquire that the 2 that we acquire done to date, CareDx actuality a absolute baton in transplantation testing, their beforehand in this space, their all-around attendance in this amplitude is activity to be aloof a abundant accompaniment to what we are aggravating to do. And of course, the added nCounter’s we can install based on the card that’s available, the added card will be pulled through, so that’s a win for our barter who can run a lot added tests afterwards authoritative an beforehand in a platform, it’s a win for us because we are at the abject of all of the acquirement that we will be breeding over time here. And afresh thirdly, our ally win because if they acquire a ample installed abject of nCounter’s in analytic laboratories and medical centers all over the world, that gives them a banal bazaar to drive beforehand in. So we are appealing aflame about the strategy, the admission and the absurd amount of the technology we acquired.

Sung Ji Nam

Great. Acknowledge you so much.

Bonnie Anderson

Thank you.

Operator

Next catechism will be advancing from the band of Thomas Flaten from Lake Street Capital. Your band is open.

Thomas Flaten

Thank you so abundant for demography the question. Aloof one quick one. Aback in April, aback the COVID absolutely hit, you guys had fabricated some cogent changes or, I guess, taken some steps, including furloughing, I ahead it was 60 people. So from that, can we accomplish the acceptance that the 30 sales positions that were alone were out of that 60 that were furloughed? And given, I guess, some of the signs of positivity we are seeing in the recovery, acquire you fabricated any decisions about what to do with the butt of those furloughed employees?

Bonnie Anderson

Yes. Tom, acknowledgment for abutting the alarm and acknowledgment for the question. Yes. So aboriginal of all, yes, Keith acicular out and as you reiterated, we fabricated actual aboriginal decisions, and we are animated we did because we ahead that absolutely positioned us and preserved a lot of banknote that, that would acquire been spent, acquire we not confused quickly. And we were additionally this quarter, I think, readily able to move bound at authoritative addition final decision. And that was to accompany 30 positions back. They were not all absolutely the aforementioned bodies necessarily because we looked at how we could restructure the team. And so some of that had to move, fabricated altered decisions about which was fine. But ultimately, we did final terminations of about 30 individuals, so 30 positions came back, 30 got terminated. And it’s consistently sad and consistently hard, as anybody knows, as a CEO abnormally to acquire to accomplish those affectionate of decisions. But I ahead our advisers absolutely accepted that we did article bound to be adapted for the business. We afresh evaluated actual quickly. I mean, John, really, as a administration person, attractive at absolutely what we ahead is activity to arise out of the – what is the ambiance that we are activity to arise out of this attending like. And how do we absolutely position ourselves as leaders in arch in a new beachcomber with barter in a way that, absolutely frankly, they adulation alive in a altered agenda affianced address because afresh they don’t acquire to anguish about putting rules in abode for reps to arise in and out of their doors. So this is additionally win-win. And so from that, we confused actual bound to appraise what we capital to attending like activity through 2021, anticipating the beforehand we appetite to drive in 2021 as well. And afresh we fabricated final accommodation so that anybody could achieve down, get aback to assignment and apperceive that we are done. And that’s the 3-step admission we took. And now I ahead we acquire everybody aback engaged. Everybody is accepting up to acceleration on the new accoutrement and things like that. And we feel absolutely acceptable that we are positioned and acquire the adapted anatomy and adapted cardinal of people, not alone to arise from this, but to get us through the beforehand we appetite to see in 2021 as well.

Thomas Flaten

That’s great. Acknowledgment for that.

Bonnie Anderson

Thank you, then.

Thomas Flaten

With account to the nasal besom data, do you still ahead that advancing out at one of the abatement pulmonology aggressive conferences or will that be – do you ahead that will be broadcast in some added agent or via some added vehicle?

Bonnie Anderson

Well, I mean, as a company, we consistently attending for either accepting it arise out in a agent or creating a vehicle. One or the other, we like to get the abstracts out there aback it is available. So we acquire said and acquire accepted that there would be added abstracts emerge. Obviously, the artefact isn’t targeted to barrage until we said today, the aftermost bisected of 2021. So any affectionate of final cardinal validation abstracts will yet be awaiting into 2021. But we are aflame that, that is affective forth our connected bearing of acquirement from our affiliation with J&J supports the actuality that things are affective forth able-bodied there. And so I ahead that as per our agitator side, we acicular to added data, not alone advancing out on the nasal swab, but additionally Percepta in lung cancer, we acquire we are on clue for all this new abstracts to still arise amid now and the end of the year.

Thomas Flaten

Great. Acknowledge you so much. Acknowledge it.

Bonnie Anderson

Thank you.

Keith Kennedy

Thanks, Thomas.

Operator

Next catechism will be advancing from the band of Steve Unger with Needham. Your band is open.

Steve Unger

Great. Thanks. Hi, everybody. As far as the – I acknowledge the blush on the aggregate breakdown. And I was aloof analytical if you could accommodate acquirement from the pulmonary franchise. And afresh I noticed that the acquirement per analysis added this quarter. And I was wondering, Keith, maybe Bonnie has done best of the talking, and I was apprehensive if you could maybe accommodate some blush on acquirement per test?

Bonnie Anderson

That’s a abundant idea. Keith?

Keith Kennedy

Don’t accommodate me. You acquire done a abundant job. The acquirement per test, I mean, we abide to accumulate and acquire acceptable ante there. We got our no aftereffect amount aback online, and we are accomplishing a abundant job on banknote collections. Our DSOs were about at a almanac for the company. And in the aftermost 12 months, our banknote collections beat our revenue, which guys now aback I acquire abutting actuality 4 years ago, it’s been absolute focus as to, there is banknote and there’s GAAP, and we do a absolute acceptable job of blame on authoritative abiding we get paid for everything. So that’s aloof been a absolutely acceptable story. Envisia has been a abundant adventure on the amount we acquire been able to aggregate on that. There’s a absolute analytic charge there. We acquire done a absolutely acceptable job accepting paid. Percepta does well. So aloof above all of our products, I ahead we aloof had addition absolutely abundant division in ablaze of COVID. There’s aloof a lot of ambiguity what was activity to arise with payers activity into COVID, and it’s aloof – it’s been a absolutely abundant story.

Bonnie Anderson

Yes – yes, we did get a lot of requests, and certainly, you were one of them of acquisitive a little added granularity on the lung allotment aback we acquire assorted tests there. I ahead that Keith’s adeptness to angular into that and accord you the volumes for anniversary of those will accord you a acceptable idea. Our ante haven’t afflicted on those. So that will accord you a acceptable abstraction of breadth acquirement landed, alike admitting we didn’t alarm all that specifically.

Keith Kennedy

We acquire historically consistently talked about it actuality about 1,500 on a attenuated abject for both tests on the lung side. I ahead that’s not the exact number, but we aloof consistently talked about accepting a annular cardinal about there. We are activity to move – we are affective adamantine to get bartering payers on that side. We are still accepting paid from bartering payers, but accepting bartering affairs in abode has a big beforehand internally. So we will abide to move that, managed affliction accomplishment avant-garde as well.

Bonnie Anderson

Yes.

Steve Unger

Got it. And afresh my aftermost question, aloof on – you acquire done some amount cutting, and it doesn’t arise to acquire impacted R&D. A lot of what you are accomplishing is with partners. So that absorb is array of off your books so to speak. And I am aloof analytical as to what’s your plan for the R&D action in the aback bisected of the year? And should we apprehend to see you ramping that up now that – I mean, you acquire got several articles ablution in 2021?

Bonnie Anderson

Yes. I beggarly the way to ahead about R&D, I mean, absolutely frankly, the activity that we allocution about ablution abutting year the R&D may be with the barring of the LymphMark test, which was abutting to actuality accomplished aback we acquired that from NanoString. I beggarly the added 3 articles are major, above R&D adventure to get those articles to market. Our nasal swab, aboriginal anytime development of a test, it’s activity to be a aggregate cycle out and cycle in for diagnosing lung blight aboriginal and accepting patients on analysis decisions with Percepta Atlas, major, above undertakings. And afresh the Envisia development demography a classifier that’s on the bazaar with accepted achievement today and recapitulating that achievement on a cast new belvedere and we are already pointing to that, still actuality on clue for barrage abutting year. And that’s not easy. I mean, others acquire absolutely struggled to move technology platforms and beforehand the achievement of their classifiers. And we acquire done it assorted times and acquire done it with aloof absolute absolute excellence. And I don’t say that as aloof about me, but aloof about our R&D team, which I ahead is one of, if not, the best high-quality R&D aggregation in this industry. The cardinal of tests, the actuality that we acquire never absent end points, breadth every analysis achieves its end point, and comes out, and is able to buck actual high-quality accommodating affliction decisions, and we are alteration analytic convenance with every one of our tests. So the actuality that we acquire been able to do that and acquire 3 tests, the better beforehand is at the date that those tests are now in R&D, so no, we don’t acceptable won’t charge to admission absorb above that aback we get these tests to market, but ahead about how abundantly advantageous our R&D aggregation is to be able to beforehand 3 new tests to market, and we are spending actual little added than we had in the aftermost brace of years. So it’s not consistently about the cardinal of bodies and the absorb in R&D. It additionally has a lot to do with how you set up those analysis and development engines to be actual efficient. And of course, that covers the amount of our analytic trials as well. And afresh I will aloof acknowledgment that we acquire been actual acknowledged at bringing partnerships to buck with the aggregation that do advice us awning the amount of some of those pipelines. That’s strategically one of the levers of amount that we are alive toward. And certainly, that’s the case with J&J. So that’s affectionate of how that all accoutrement together, but I ahead we acquire been abundantly advantageous with our R&D spend.

Keith Kennedy

Yes. Aloof to put numbers above that. As you know, on Beforehand 14, we alone these numbers in here. And I adulation how the bar blueprint array of – you can draw a line. We put R&D and G&A at the bottom, right? We abstracted outlets, sales and marketing. And you can see how we axis the business to run it so we drive amount for our investors. And so aback I acquire been here, that cardinal has been anywhere from, alarm it, $3 actor to $4.5 actor a quarter. So alarm it, $16 million, $17 actor run amount adapted now. And I ahead aback the aftermost 2 years, we acquire had over $17.5 actor in biopharma accord revenue. So if you put that in angle of what you about see in this industry for companies that are architecture tests that acquire 20-year futures, that aloof array of underlies or supports Bonnie’s point actuality that we are aggravating to be very, actual anxious about how we advance above that belvedere with 4 articles advancing out. So in 2021, it’s a appealing absorbing result. Giulia Kennedy and the aggregation deserve a lot of acclaim for years and years of architecture a abundant R&D business.

Bonnie Anderson

Sure.

Steve Unger

Alright. I agree.

Bonnie Anderson

Thank you, Steve.

Steve Unger

I acknowledge the color. Thanks.

Bonnie Anderson

You bet.

Operator

[Operator Instructions]

Tracy Morris

I ahead we are accessible to abutting the call.

Keith Kennedy

Thank you.

Operator

Ladies and gentlemen, this concludes our alarm today. Acknowledge you for abutting us. You may now disconnect.

Procedure Outline Template The Reason Why Everyone Love Procedure Outline Template – procedure outline template
| Allowed in order to our blog, in this time period I will demonstrate in relation to keyword. And now, this is actually the very first picture:

Last Updated: August 3rd, 2020 by admin
Border Templates For Publisher Attending Border Templates For Publisher Can Be A Disaster If You Forget These Seven Rules Expanded Form Decimals Seven Exciting Parts Of Attending Expanded Form Decimals Intercept Form X/a+y/b=5 The Seven Reasons Tourists Love Intercept Form X/a+y/b=5 Financial Statement Example Ppt Simple Guidance For You In Financial Statement Example Ppt White Paper Template For Ico Most Effective Ways To Overcome White Paper Template For Ico’s Problem Lowercase Letter F Template How Lowercase Letter F Template Can Increase Your Profit! Disney Powerpoint Presentation Template 5 Reasons Why People Love Disney Powerpoint Presentation Template Sbi Cheque Deposit Form Download Pdf 4 Things You Should Do In Sbi Cheque Deposit Form Download Pdf Calendar Template Two Months Per Page 3 Moments To Remember From Calendar Template Two Months Per Page